Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Technology Innovation of the Year Award for Prostate Cancer Diagnosis, 2010

Technology Innovation of the Year Award Prostate Cancer Diagnosis for, 2010
CLICK TO READ MORE

BEST PRACTICES RESEARCH

Technology Innovation of the Year Award
Prostate Cancer Diagnosis
North America, 2010

Frost & Sullivan’s Global Research Platform

Frost & Sullivan is entering its 50th year in business as a global research organization with 1,800 analysts and consultants who monitor more than 300 industries and 250,000 companies. The Company’s research philosophy originates with the CEO’s 360 Degree Perspective,* which in turn serves as the foundation for its TEAM Research** methodology. This unique approach enables us to determine how best-in-class companies worldwide manage growth, innovation and leadership. Based on the findings using this Best Practices research, Frost & Sullivan is proud to present the 2010 North American Technology Innovation of the Year Award in Prostate Cancer Diagnosis to Hybridyne Imaging Technologies, Inc.

Significance of the Technology Innovation of the Year Award

Key Industry Challenges Addressed by New Technology Innovation
Prostate cancer is the second leading cause of cancer related mortalities in men. Commonly used diagnostic tests for prostate cancer include blood testing to measure the level of prostate specific antigen (PSA), ultrasound imaging, and nuclear imaging techniques, such as PET and SPECT. However, all of these tests have limitations and lack specificity with respect to the detection of benign and cancerous lesions. As blood tests cannot lead to a differential diagnosis between benign and malignant lesions, physicians further recommend yet another invasive test – the biopsy - for a confirmative diagnosis. Similarly, with ultrasound imaging, benign fibrous tissues caused by previous radiation treatments are likely to be misdiagnosed as malignant tumors. The most promising nuclear imaging methods, PET and SPECT, produce poor resolution images. Most commercially available gamma cameras cannot image tumors less than 1 to 5 mm size within the anatomical site of interest, making these less efficient for prostate cancer diagnosis. Moreover, the detectors used in these systems are too large and are not amenable for endoscopic investigations. All of these limitations have in turn led to significant numbers of missed early and post-operative cancer detections and false negative biopsy results, creating the need for a technology that can detect early-stage tumors and show them in fine detail.

Frost & Sullivan consistently tracks and monitors emerging technologies for cancer diagnosis and affirms the need for potential life-changing offerings. ProxiScan – a miniaturized gamma camera and probe developed by a Canadian firm, Hybridyne Imaging Technologies, Inc. - has emerged as the ultimate technology capable of high-spatial resolution imaging and detecting prostate tumors, which are almost 10 times smaller than the minimal detectable limit for conventional gamma cameras and are constantly missed by such systems

2010 WBT showcase Press Release
Hybridyne 
Imaging 
Technologies 
and 
Brookhaven 
National 
Laboratory Featured 
at 
the 
2010 
WBT showcase
CLICK TO READ MORE

NEWS 
RELEASE

For release: March 2, 2010
contact: Terry Lall, 416 218-5578, tcalinc@rogers.com, or
Diane Greenberg, 631 344-2347, greenb@bnl.gov

Hybridyne 
Imaging
 Technologies 
and 
Brookhaven 
National 
Laboratory 
to 
be 

Featured
 at 
the 
2010 
WBT showcase

Premier 
Emerging 
Tech 
Forum 
Offers 
Matchmaking
 Prospects 
for 
Hybridyne's 

Medical
 Imaging 
Technology 
for 
Detecting 
Prostate 
Cancer

March,
 2010 
| 
Arlington, 
TX 
– Hybridyne
 Imaging
 Technologies,
 Inc., 
and 
the
 U.S. 

Department 
of 
Energy's 
Brookhaven
 National
 Laboratory
 are 
among 
over 
100

companies 
and 
technology
 innovators 
from 
across 
the 
nation 
and 
around 
the 
world 

that 
will 
compete 
for 
top 
honors 
at 
the 
WBT 2010, 
March 
16‐17,
 in 
Arlington‐DFW, 

Texas.
 The 
WBT showcase 
in 
the 
world's 
largest 
forum 
for 
connecting 
pre‐screened 

technologies 
and 
companies 
with 
licensees 
and 
investors.

Hybridyne's 
technology, 
called 
ProxiScan TM,
 is 
capable
 of 
high‐resolution 
imaging 
of 

prostate
 cancer. 
The 
unique 
component 
of 
the 
technology 
is 
a 
cadmium
zinc 

telluride
 (CZT) ‐ based 
compact 
gamma 
camera 
developed 
in 
collaboration 
with 

Brookhaven 
Lab 
scientists.

Hybridyne 
will 
present 
its 
new 
imaging 
technology 
to 
for um
participants 
and 

commercialization 
experts 
at 
WBT 2010. 
Over
 500 
professionals,
 including 
venture 

capitalists 
and 
for tune 
1000
 liscensees,
 attended
 last 
year’s
event.

“ The 
conventional 
wisdom 
for 
venture 
capital
is
t hat 
a 
down 
economy 
can 
be 
a 
great 

time 
to 
invest, ”
 said 
Paul 
Huleatt, 
WBT showcase 
CEO. 
“ The 
pace 
of 
new 
innovations 

accelerates, 
the 
best 
deals 
rise
 quickly
 to 
the 
top 
and 
the 
sophisticated 
investors 

receive 
great 
value 
for 
their 
money.”

According
 to 
Mr.
Huleatt, 
one 
in 
three 
WBT showcase 
presenters 
goes 
on 
to 
secure 

venture 
funding,
 license
 the 
featured 
technology, 
or 
sell 
the 
showcased 
invention

outright, 
representing 
over 
$450 
million 
raised 
to 
date.

Terry
Lall, 
Hybridyne's
 President
 and 
CEO 
said, 
“One 
in 
six 
men 
in 
the 
U.S. 
will
 be

diagnosed 
with 
prostate 
cancer 
in 
his 
lifetime, 
and 
one 
in 
35 
will 
die 
from 
the.....


 

Press Release March 25th, 2010
Hybridyne 
Imaging 
Technologies 
­ 
Brookhaven 
National 
Laboratory
 Team Vies 
for 
Top 
Title 
at 
the 
2010 
WBT showcase
CLICK TO READ MORE

NEWS 
RELEASE

For release: March 25, 2010
contact: Terry Lall, 416 218-5578, tcalinc@rogers.com, or
Diane Greenberg, 631 344-2347, greenb@bnl.gov

Hybridyne 
Imaging 
Technologies
­
Brookhaven 
National
 Laboratory
 Team
Vies
 for 
Top 
Title 
at 
the 
2010 
WBT showcase

Toronto/Ontario ­ based 
Medical
 Imaging 
Technology 
Among 
90 
Selected 
for

Global
 Showcase

March, 
2010 
| 
Arlington, 
TX
 – A 
team 
from 
Hybridyne 
Imaging 
Technologies, 
Inc.,

and 
the 
U.S. 
Department 
of 
Energy's 
Brookhaven 
National
 Laboratory 
was 
among

over 
90 
top 
technology
 innovators 
from 
across
 the 
nation 
and 
around 
the 
world

competing 
in 
Arlington, 
Texas, 
March 16 ‐17, 
for 
top 
honors 
at 
the

WBT 2010 show case 
presented 
by 
Lockheed 
Martin.

Hybridyne's 
technology, 
called 
ProxiScan™, 
is 
capable 
of 
high‐resolution 
imaging 
of

prostate 
cancer.
 The 
unique 
component 
of 
the 
technology
 is 
a 
cadmium
zinc

telluride 
(CZT) ‐ based 
compact 
gamma
 camera 
developed 
in 
collaboration 
with

Brookhaven 
Lab 
scientists.
 The 
technology 
was 
presented 
to 
a 
sold ‐ out 
WBT 2010

audience 
of 
over 
600 
participants, 
including
 venture 
capital
 investors, 
federal

agencies 
and 
licensees.

“The 
word 
is 
out 
that 
for 
investors, 
federal
 agencies 
and
 licensees 
seeking 
emerging

technology 
opportunities, 
WBT 
offers 
the 
best 
deal
 flow 
in 
the 
nation,” 
said 
Paul

Huleatt, 
WBT’s 
CEO.

 “We 
look 
forward 
to 
watching 
the 
progress 
of 
our 
WBT 2010

presenters.”


According 
to 
Mr. 
Huleatt, 
approximately 
one ‐ third 
of 
past 
WBT 
presenters
 have

gone 
on 
to 
secure
 venture 
capital
 or 
a 
licensing / strategic 
partnership 
agreement.


To
date, 
past 
presenters 
have 
raised 
over 
$450 
million 
in 
first 
( or 
next )
 round

venture 
capital.

Terry
Lall, 
Hybridyne's 
President
and 
CEO
said, 
“One 
in 
six 
men 
in 
the 
U.S. 
will
 be

diagnosed 
with 
prostate 
cancer 
in 
his 
lifetime, 
and 
one 
in 
35 
wil l
die 
from
 the

disease. 

Prostate 
cancer 
is 
the 
second
 leading 
cause 
of 
cancer 
deaths 
in 
men

because 
there 
is 
no 
technology 
able 
to 
detect 
tumors 
at 
an 
early 
stage 
and 
localize.....

 
 
 
   
Copyright 2011 Hybridyne Imaging Technologies, Inc. All rights reserved.